Shiny new startup Egle grabs a deal with Takeda for cancer research

It only officially launched in early 2020 but Egle Therapeutics is not hanging around, penning a new R&D deal with Japanese pharma Takeda.

It’s not big numbers: Takeda will invest €4.6 million in convertible debt through its venture arm, but will tap Paris, France-based Egle to help uncover new tumor-specific regulatory T-cell targets, as well as working on anti-suppressor-based immunotherapies.